Prostate cancer selective radioactive prodrug

Ended Definitive Contract Awarded Last action

Contract number
HHSN261201600016C
Awardee
Awarding agency
Obligated
$298,882

Award facts

Opportunity
  • PHS20161 Solicitation number
Contract value 100% obligated
$298,882.00 Current and potential, with all options
Completion date 100% complete
Current and potential, with all options
Set-aside
Total Small Business
Competition
Full and Open Competition after exclusion of sources · 12 offers Negotiated Proposal / Quote
Pricing
Firm Fixed Price
Place of performance
Cambridge, MA 02142, USA
Research
SBIR Program Phase I Action

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Supplemental Agreement for work within scope 1 $0
Original award $298,882

About this award

The National Cancer Institute (NCI) awarded a Small Business Innovation Research (SBIR) Program Phase I contract to Oncotherapeutica, Inc. for the development of a "Prostate Cancer Selective Radioactive Prodrug". This $298,882 Firm Fixed Price contract was awarded on September 19, 2016 and has a completion date of November 18, 2017. The contract is designated as a Total Small Business set-aside.

Quick answers

Who was awarded contract HHSN261201600016C?

HHSN261201600016C was awarded to Oncotherapeutica, Inc. by National Cancer Institute (National Institutes of Health) on September 19, 2016.

How much is contract HHSN261201600016C worth?

The government has obligated $298,882 on HHSN261201600016C.

Was contract HHSN261201600016C competed?

The extent of competition for HHSN261201600016C was full and open competition after exclusion of sources. The government received 12 offers. It was set aside: Total Small Business.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award